ZIOPHARM Oncology (ZIOP) is Reiterated by Mizuho to Neutral, Raises Price Target to $ 7

ZIOPHARM Oncology (ZIOP) was Reiterated by Mizuho to “Neutral” according to the research note released today. The brokerage firm has raised the Price Target to $ 7 from a previous price target of $6 . Mizuho advised their investors in a research report released on May 11, 2016.

On the company’s financial health, ZIOPHARM Oncology reported $-0.09 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 10, 2016. Analyst had a consensus of $-0.08. The company had revenue of $1.97 million for the quarter, compared to analysts expectations of $1.89 million. The company’s revenue was up 623.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.69 EPS.

ZIOPHARM Oncology opened for trading at $7.42 and hit $7.78 on the upside on Tuesday, eventually ending the session at $7.48, with a gain of 0.94% or 0.07 points. The heightened volatility saw the trading volume jump to 22,37,769 shares. Company has a market cap of $985 M.

In a different news, on Nov 23, 2015, Caesar J Belbel (COO, CLO, and Secretary) sold 153,333 shares at $12.84 per share price. According to the SEC, on Jun 11, 2015, Francois Lebel (Executive Vice President R&D) sold 50,000 shares at $10.12 per share price. On Jun 5, 2015, Kevin G Lafond (Vice Pres., Treasurer, & CAO) sold 57,500 shares at $9.67 per share price, according to the Form-4 filing with the securities and exchange commission.

ZIOPHARM Oncology Inc. is a biopharmaceutical company. The Company is engaged in the acquisition development and commercialization of a portfolio of cancer therapies through synthetic biology. The Company’s pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Company’s clinical stage product candidate Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12 or IL-12 a potent naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex for the treatment of metastatic melanoma and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).


Leave a Reply

ZIOPHARM Oncology - Is it time to Sell?

Top Brokerage Firms are advising their investors on ZIOPHARM Oncology. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.